COVID-19 Vaccination Coverage in Italy: How Many Hospitalisations and Related Costs Could Have Been Saved If We Were All Vaccinated?
作者信息
Zamagni Giulia, Armocida Benedetta, Abbafati Cristiana, Ronfani Luca, Monasta Lorenzo
机构信息
Clinical Epidemiology and Public Health Research Unit, Institute for Maternal and Child Health-IRCCS "Burlo Garofolo", Trieste, Italy.
Department of Juridical and Economic Studies, Sapienza University of Rome, Rome, Italy.
出版信息
Front Public Health. 2022 Mar 3;10:825416. doi: 10.3389/fpubh.2022.825416. eCollection 2022.
Abstract
摘要
相似文献
1
COVID-19 Vaccination Coverage in Italy: How Many Hospitalisations and Related Costs Could Have Been Saved If We Were All Vaccinated?
Front Public Health. 2022 Mar 3;10:825416. doi: 10.3389/fpubh.2022.825416. eCollection 2022.
2
Guidance for Implementing COVID-19 Prevention Strategies in the Context of Varying Community Transmission Levels and Vaccination Coverage.
MMWR Morb Mortal Wkly Rep. 2021 Jul 27;70(30):1044-1047. doi: 10.15585/mmwr.mm7030e2.
3
Seeking to address issues with COVID-19 vaccines in Japan and to resolve global problems with vaccination programmes.
Int Marit Health. 2021;72(2):142. doi: 10.5603/IMH.2021.0024.
4
COVID-19 Vaccination Coverage and Intent Among Adults Aged 18-39 Years - United States, March-May 2021.
MMWR Morb Mortal Wkly Rep. 2021 Jun 25;70(25):928-933. doi: 10.15585/mmwr.mm7025e2.
5
Estimating averted COVID-19 cases, hospitalisations, intensive care unit admissions and deaths by COVID-19 vaccination, Italy, January-September 2021.
Euro Surveill. 2021 Nov;26(47). doi: 10.2807/1560-7917.ES.2021.26.47.2101001.
6
SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status - Los Angeles County, California, May 1-July 25, 2021.
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1170-1176. doi: 10.15585/mmwr.mm7034e5.
7
COVID-19 Vaccination Coverage Among Insured Persons Aged ≥16 Years, by Race/Ethnicity and Other Selected Characteristics - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 15, 2021.
MMWR Morb Mortal Wkly Rep. 2021 Jul 16;70(28):985-990. doi: 10.15585/mmwr.mm7028a1.
8
Should Canada's approach to COVID-19 and kids change with new variants?
CMAJ. 2021 Apr 26;193(17):E623-E624. doi: 10.1503/cmaj.1095936.
9
Modelling direct and herd protection effects of vaccination against the SARS-CoV-2 Delta variant in Australia.
Med J Aust. 2021 Nov 1;215(9):427-432. doi: 10.5694/mja2.51263. Epub 2021 Oct 11.
10
Tackling inequitable distribution of the COVID-19 vaccine.
Br J Community Nurs. 2021 Jan 2;26(1):48-49. doi: 10.12968/bjcn.2021.26.1.48.
引用本文的文献
1
COVID-19 recognition from chest X-ray images by combining deep learning with transfer learning.
Digit Health. 2025 Feb 13;11:20552076251319667. doi: 10.1177/20552076251319667. eCollection 2025 Jan-Dec.
2
Strategic vaccination responses to Chikungunya outbreaks in Rome: Insights from a dynamic transmission model.
PLoS Negl Trop Dis. 2024 Dec 9;18(12):e0012713. doi: 10.1371/journal.pntd.0012713. eCollection 2024 Dec.
3
A Serological Analysis of the Humoral Immune Responses of Anti-RBD IgG, Anti-S1 IgG, and Anti-S2 IgG Levels Correlated to Anti-N IgG Positivity and Negativity in Sicilian Healthcare Workers (HCWs) with Third Doses of the mRNA-Based SARS-CoV-2 Vaccine: A Retrospective Cohort Study.
Vaccines (Basel). 2023 Jun 23;11(7):1136. doi: 10.3390/vaccines11071136.
4
Integration of Cellular and Humoral Immune Responses as an Immunomonitoring Tool for SARS-CoV-2 Vaccination in Healthy and Fragile Subjects.
Viruses. 2023 May 30;15(6):1276. doi: 10.3390/v15061276.
本文引用的文献
1
Waning Immunity after the BNT162b2 Vaccine in Israel.
N Engl J Med. 2021 Dec 9;385(24):e85. doi: 10.1056/NEJMoa2114228. Epub 2021 Oct 27.
2
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.
Lancet. 2021 Oct 16;398(10309):1407-1416. doi: 10.1016/S0140-6736(21)02183-8. Epub 2021 Oct 4.
3
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months.
N Engl J Med. 2021 Dec 9;385(24):e84. doi: 10.1056/NEJMoa2114583. Epub 2021 Oct 6.
4
Relaxing restrictions at the pace of vaccination increases freedom and guards against further COVID-19 waves.
PLoS Comput Biol. 2021 Sep 2;17(9):e1009288. doi: 10.1371/journal.pcbi.1009288. eCollection 2021 Sep.
5
Economic value of vaccines to address the COVID-19 pandemic: a U.S. cost-effectiveness and budget impact analysis.
J Med Econ. 2021 Jan-Dec;24(1):1060-1069. doi: 10.1080/13696998.2021.1965732.
6
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
7
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
8
The potential long-term impact of the COVID-19 outbreak on patients with non-communicable diseases in Europe: consequences for healthy ageing.
Aging Clin Exp Res. 2020 Jul;32(7):1189-1194. doi: 10.1007/s40520-020-01601-4. Epub 2020 May 26.
9
Covid-19: risk factors for severe disease and death.
BMJ. 2020 Mar 26;368:m1198. doi: 10.1136/bmj.m1198.
10
National Immunization Therapeutic Advisory Group: it is time for experience sharing and best practice learning.
J Mark Access Health Policy. 2015 Sep 14;3. doi: 10.3402/jmahp.v3.29276. eCollection 2015.
Zotero 插件